L&C Bio엘앤씨바이오
290650 · KOSDAQ · ₩290650 · 엘앤씨바이오
₩24,950▲ ₩1,150 (4.83%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩85B | ₩72B | ₩69B | ₩53B | ₩46B |
| Cost of sales | ₩40B | ₩36B | ₩34B | ₩26B | ₩17B |
| Gross profit | ₩45B | ₩36B | ₩35B | ₩27B | ₩28B |
| Operating income | ₩4.4B | ₩2.5B | ₩7.7B | ₩9.5B | ₩13B |
| Net income | −₩138B | ₩141B | ₩49B | ₩5.7B | ₩16B |
| Net income to shareholders | −₩138B | ₩141B | ₩48B | ₩4.5B | ₩14B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩457B | ₩476B | ₩262B | ₩200B | ₩107B |
| Current assets | ₩139B | ₩130B | ₩130B | ₩64B | ₩48B |
| Cash and equivalents | ₩31B | ₩18B | ₩15B | ₩6.6B | ₩17B |
| Total liabilities | ₩248B | ₩181B | ₩105B | ₩92B | ₩14B |
| Current liabilities | ₩238B | ₩155B | ₩102B | ₩19B | ₩5.6B |
| Borrowings | ₩86B | ₩119B | ₩80B | ₩80B | ₩5.6B |
| Total equity | ₩209B | ₩295B | ₩157B | ₩108B | ₩93B |
| Shareholders' equity | ₩198B | ₩284B | ₩147B | ₩98B | ₩85B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩13B | −₩8.6B | −₩12B | −₩6.1B | ₩11B |
| Capital spending | ₩16B | ₩4.7B | ₩25B | ₩38B | ₩10B |
| Free cash flow | −₩3.2B | −₩13B | −₩37B | −₩44B | ₩656M |
| Dividends paid | ₩1.1B | ₩2.3B | ₩1.1B | ₩1.1B | ₩1.1B |
Consolidated where available. Amounts in won.
Also known as: L&C Bio / 엘앤씨바이오 / 290650 / KRX:290650
Source: KRX statistical information